OvaWatch® – Aspira Women's Health

Redefine Ovarian Care for Adnexal Masses

OvaWatch is a non-invasive blood test intended to assess the risk of ovarian cancer in patients with an adnexal mass initially evaluated as indeterminate or benign to personalize treatment.

Order Test Kits

Name(Required)

First Last

Email(Required)

Phone(Required)

NPI Number(Required)

Number of Kits

Address(Required)

Street Address Address Line 2 City State / Province / Region ZIP / Postal Code Country

Refine Care from Uncertainty to Confidence

High Negative Predictive Value

With a negative predictive value over 99%, a lower OvaWatch score indicates a very low probability of malignancy for confidence and peace of mind^¹.

Longitudinal Monitoring Feature

The Longitudinal Monitoring feature of OvaWatch provides the patient's individualized ovarian cancer risk assessment over time, enabling a dynamic and comprehensive view of a patient’s risk profile.

Easy-to-Read Reports

Results are presented in an easy-to-read format, facilitating clear communication between healthcare providers and patients.

A recent study indicates that using OvaWatch could have led to a potential3:

overall reduction in avoidable adnexal mass surgeries

reduction of surgical referrals among asymptomatic patients

reduction of surgical referrals among premenopausal patients

DOWNLOAD THE CLINICAL SUMMARY

One Simple Blood Draw.
Many Benefits.

Utilizing OvaWatch could:

Provide confidence in a non-surgical, watch-and-wait approach, not uncertainty

Help back up clinical decisions with objective, biomarker-based data

Potential to reduce surgeries on adnexal masses

Order TEST KITS

Clinical Advantages for Ease & Convenience

MULTIPLE BIOMARKERS

Our products use an advanced, evidence-based algorithm incorporating multiple biomarkers

LONGITUDINAL MONITORING

This feature enables providers to perform ongoing, point-in-time, personalized ovarian cancer risk assessments for continued confidence

SIMPLE & OBJECTIVE

One simple blood draw provides an objective risk score within 48 hours

The OvaWatch Report

The OvaWatch report includes a new longitudinal monitoring feature to provide ongoing, point-in-time, personalized ovarian cancer assessments

Enhance Standard of Care with Data-Driven Decisions

Make informed decisions at every stage with OvaWatch's advanced, evidence-based risk scores generated from a proprietary algorithm incorporating:

Age

Menopausal status

7 biomarkers (including CA-125 and HE4)

Order Test Kits

OvaWatch empowers healthcare providers to transform uncertainty into fact-based ovarian care throughout the patient's journey.

Order Test Kits

Planning for surgery?

Learn about Ova1Plus

References

Reilly, G., Bullock, R. G., Greenwood, J., Ure, D. R., Stewart, E., Davidoff, P., ... & Northrop, L. E. (2022). Analytical validation of a deep neural network algorithm for the detection of ovarian cancer. JCO Clinical Cancer Informatics, 6, e2100192.
Bristow, R. E., Smith, A., Zhang, Z., Chan, D. W., Crutcher, G., Fung, E. T., & Munroe, D. G. (2013). Ovarian malignancy risk stratification of the adnexal mass using a multivariate index assay. Gynecologic oncology, 128(2), 252-259.
Choudhury, M. Roy, Pappas, T. C., Twiggs, L. B., Caoili, E., Fritsche, H., & Phan, R. T. (2024). Ovarian Cancer surgical consideration is markedly improved by the neural network powered-MIA3G multivariate index assay. Frontiers in Medicine, 11, 1374836.
Dunton, C. J., Hutchcraft, M. L., Bullock, R. G., Northrop, L. E., & Ueland, F. R. (2021). Salvaging detection of early-stage ovarian malignancies when CA125 is not informative. Diagnostics, 11(8), 1440.
ACOG Practice Bulletin Number 174, November 2016
SGO Position Statement Issued 2011, Updated 2013
American College of Obstetricians and Gynecologists’ Committee on Practice Bulletins—Gynecology. Practice Bulletin No. 174: Evaluation and Management of Adnexal Masses. Obstet Gynecol. 2016 Nov;128(5):e210-e226. doi: 10.1097/AOG.0000000000001768. PMID: 27776072.
Castillo G, Alcázar JL, Jurado M. Natural history of sonographically detected simple unilocular adnexal cysts in asymptomatic postmenopausal women. Gynecol Oncol 2004; 92:965.
Pavlik EJ, Ueland FR, Miller RW, et al. Frequency and disposition of ovarian abnormalities followed with serial transvaginal ultrasonography. Obstet Gynecol 2013; 122:210.
Ueland, F. R., & Fredericks, N. I. (2018). Ovarian masses: Surgery or surveillance. OBG Manag, 30(6), 17-26.
Cleveland Clinic. (n.d.). Adnexal mass (tumor): Symptoms, causes & treatment. Cleveland Clinic. https://my.clevelandclinic.org/health/diseases/22015-adnexal-mass-tumors
Eskander, R., Berman, M., & Keder, L. (2016). Evaluation and management of adnexal masses. Obstetrics and Gynecology, 128(5), e210-e226.
Alcázar, J. L., Pascual, M. A., Graupera, B., Aubá, M., Errasti, T., Olartecoechea, B., ... & Guerriero, S. (2016). External validation of IOTA simple descriptors and simple rules for classifying adnexal masses. Ultrasound in Obstetrics & Gynecology, 48(3), 397-402.
Kingsberg, S. A., Larkin, L. C., & Liu, J. H. (2020). Clinical effects of early or surgical menopause. Obstetrics & Gynecology, 135(4), 853-868.

PRECAUTION: OvaWatch is intended for use as a non-invasive test to assess the risk of ovarian cancer for women with adnexal masses, evaluated by initial clinical assessment (ICA) as indeterminate or benign. In conjunction with imaging (ultrasound and/or CT) and clinical assessment, this test will support physicians in making informed clinical decisions in the management of women with adnexal masses. The test is not intended as a screening test or a stand-alone diagnostic assay.

Understanding pelvic masses

Treatment plan options

What to expect

Ongoing support

Assessing a pelvic mass

Testing an indeterminate or likely benign pelvic mass

Testing a pelvic mass with planned surgery

How does the test work?

Redefine Ovarian Care for Adnexal Masses

Refine Care from Uncertainty to Confidence

A recent study indicates that using OvaWatch could have led to a potential3:

One Simple Blood Draw.
Many Benefits.